Bayer HealthCare Pharmaceuticals Inc. has notified the FDA that the company will start removing the remaining Trasylol stock from the U.S. market, most of which is in warehouses and hospital or physicians stock. The FDA will work with Bayer to ensure a smooth and complete process.
Original post by Food and Drug Administration Press Releases
Share and Enjoy:
These icons link to social bookmarking sites where readers can share and discover new web pages.
This entry was posted on Wednesday, May 14th, 2008 at 3:53 pm and is filed under FDA NEWS DIGEST. You can follow any responses to this entry through the RSS 2.0 feed.
Responses are currently closed, but you can trackback from your own site.